1. CHFR-mediated degradation of RNF126 confers sensitivity to PARP inhibitors in triple-negative breast cancer cells
- Author
-
Wenjing Wu, Xiaojuan Xie, Limin Xie, Weijun Wu, Kaishun Hu, Chaoye Yang, Dong Yin, Jianli Zhao, and Jianhong Xiao
- Subjects
Cell Survival ,Ubiquitin-Protein Ligases ,Poly ADP ribose polymerase ,Poly (ADP-Ribose) Polymerase-1 ,Biophysics ,Cell Cycle Proteins ,Triple Negative Breast Neoplasms ,Poly(ADP-ribose) Polymerase Inhibitors ,Biochemistry ,PARP1 ,Ubiquitin ,CHFR ,Tumor Cells, Cultured ,Humans ,Poly-ADP-Ribose Binding Proteins ,Molecular Biology ,Triple-negative breast cancer ,biology ,Chemistry ,Intracellular vesicle ,Cell Biology ,Neoplasm Proteins ,Up-Regulation ,Ubiquitin ligase ,PARP inhibitor ,biology.protein ,Cancer research ,Phthalazines - Abstract
Ring-finger protein 126 (RNF126), an E3 ubiquitin ligase, plays crucial roles in various biological processes, including cell proliferation, DNA damage repair, and intracellular vesicle trafficking. Whether RNF126 is modulated by posttranslational modifications is poorly understood. Here, we show that PARP1 interacts with and poly(ADP)ribosylates RNF126, which then recruits the PAR-binding E3 ubiquitin ligase CHFR to promote ubiquitination and degradation of RNF126. Moreover, RNF126 is required for the activation of ATR-Chk1 signaling induced by either irradiation (IR) or a PARP inhibitor (PARPi), and depletion of RNF126 increases the sensitivity of triple-negative breast cancer (TNBC) cells to PARPi treatment. Our findings suggest that PARPi-mediated upregulation of RNF126 protein stability contributes to TNBC cell resistance to PARPi. Therefore, targeting the E3 ubiquitin ligase RNF126 may be a novel treatment for overcoming the resistance of TNBC cells to PARPi in clinical trials.
- Published
- 2021